University of Cambridge > Talks.cam > Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer > First in human evaluation of CDK9 inhibition with KB-0742 in solid tumors

  Browse A-Z

Log in

Cambridge users (raven)details Other usersdetails No account?details

Information on

Subscribing to talksdetails Finding a talkdetails Adding a talkdetails Disseminating talksdetails Help and Documentationdetails

First in human evaluation of CDK9 inhibition with KB-0742 in solid tumors

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Kate Davenport.

Please note this seminar is on a Monday

KB-0742, is a CDK9 inhibitor, that originated from a Kronos Bio proprietary drug screen. CDK9 is a global regulator of transcription and a critical node in multiple oncogenic transcription regulated networks. KB-0742 is in an ongoing Phase 1/2 study. Details of the study will be presented.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.

Other lists

links you can check Mental Health Life Course Lecture Series dh539

Other talks

The mechanical phase transition organizing cartilage shear mechanics and function. LMB Seminar: Pharmacological Adaptation of Proteostasis to Ameliorate Aging-associated Degenerative Diseases Expanding neurobiological models of adolescence - threat learning, extinction and cortical plasticity Short Cuts Leader, Follower, and Cheaters in Collective Cancer Invasion Geometric Frustration and Modulated Phases in Liquid Crystals
 

© 2006-2024 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity